Amag Pharmaceuticals Inc., of Waltham, Mass., reported first quarter revenues of $89.5 million, compared with $20.8 million in the first quarter of 2014, primarily due to an increase of 85 percent in sales of Makena (hydroxyprogesterone caproate) over the period, to $55.5 million.